Novo Nordisk’s Amycretin Delivers Strong Phase 2 Results in Type 2 Diabetes

Novo Nordisk’s Amycretin Delivers Strong Phase 2 Results in Type 2 Diabetes

By, Admin 28 November 2025

Novo Nordisk has revealed positive Phase 2 results for amycretin, a new dual-agonist targeting GLP-1 and amylin receptors. This is the first time amycretin has been tested in people with type 2 diabetes.

What Amycretin Is?

Amycretin is a unimolecular GLP-1 and amylin receptor agonist. It is being developed in:

  • Once-weekly subcutaneous form
  • Once-daily oral form

Both are designed to improve glucose control and drive meaningful weight loss.

Why This Trial Matters?

Most patients still struggle to reach stable HbA1c and weight targets. A dual-pathway therapy that hits glucose, appetite, and weight could shift the treatment landscape.

Amycretin’s early data points in that direction.

Key Phase 2 Highlights

Glycemic Control

Once-weekly subcutaneous amycretin

  • HbA1c drop: up to –1.8%
  • HbA1c <7% achieved by 89.1%
  • HbA1c ≤6.5% achieved by 76.2%

Once-daily oral amycretin

  • HbA1c drop: up to –1.5%
  • HbA1c <7% achieved by 77.6%
  • HbA1c ≤6.5% achieved by 62.6%

Placebo comparison

  • Only –0.2% (subcutaneous) and –0.4% (oral)

All results were statistically significant.

Massive Weight Loss Without a Plateau

Subcutaneous amycretin

  • Up to 14.5% weight loss
  • Placebo: –2.6%

Oral amycretin

  • Up to 10.1% weight loss
  • Placebo: –2.5%

No plateau was observed at week 36, even at higher doses.

Trial Overview at a Glance

  • 448 participants with type 2 diabetes
  • All were inadequately controlled on metformin, with or without SGLT2 inhibitors
  • ~40% were already using SGLT2 inhibitors
  • Six subcutaneous doses (0.4–40 mg weekly)
  • Three oral doses (6–50 mg daily)
  • Duration: up to 36 weeks

Safety Profile

Amycretin was well tolerated. Side effects were mainly gastrointestinal and mostly mild to moderate. Safety aligned with other incretin and amylin-based therapies.

The Quote That Says It All

Martin Holst Lange, CSO at Novo Nordisk:

“The data further validate the potential best-in-class profile of amycretin… We look forward to an extensive phase 3 program in 2026.”

What Happens Next?

Novo Nordisk plans to begin a phase 3 development program in 2026 for adults with type 2 diabetes. Additional indications are also being explored.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!